An Introduction to Liver Cancer Treatment
The management of primary liver cancer, most commonly hepatocellular carcinoma (HCC), is exceptionally complex because it involves treating two distinct medical conditions simultaneously: the cancer itself and the underlying chronic liver disease, such as cirrhosis, which is present in the majority of patients.
The choice of treatment is therefore guided by a careful assessment of both the cancer’s stage and the patient’s liver function. Key factors include the number and size of tumors, whether the cancer has invaded blood vessels, if it has spread beyond the liver, and the overall health of the liver. Treatment goals can range from curative, aiming for complete elimination of the cancer, to palliative, focused on slowing the cancer’s progression, managing symptoms, and preserving quality of life.
The Essential Role of the Multidisciplinary Liver Cancer Team
Given the complexity of balancing cancer treatment with liver health, a collaborative, multidisciplinary team (MDT) approach is the standard of care. This ensures that every patient benefits from a range of specialized expertise, leading to a comprehensive and highly coordinated treatment plan.
The core members of a liver cancer MDT include:
- Hepatologist: A specialist in liver diseases who manages the underlying liver condition (e.g., cirrhosis) and assesses liver function to determine which treatments a patient can safely tolerate.
- Surgical Oncologist or Transplant Surgeon: A surgeon specializing in operating on the liver, performing procedures like tumor removal (resection) or liver transplantation.
- Interventional Radiologist: A physician who performs minimally invasive, image-guided procedures, such as ablation and embolization, which are cornerstones of liver cancer treatment.
- Medical Oncologist: A physician who treats advanced liver cancer with systemic medications, including targeted therapy and immunotherapy.
- Radiation Oncologist: A specialist who plans and delivers radiation therapy.
- Pathologist and Radiologist: Physicians who diagnose the cancer through tissue samples and interpret imaging scans (CT, MRI) to stage the disease.
Key Factors Guiding Treatment Decisions
Two main classification systems are used to guide liver cancer treatment: one to assess liver function and one to stage the cancer.
- Liver Function (Child-Pugh Score): Before any treatment is considered, the patient’s liver function is assessed, often using the Child-Pugh score. This score evaluates factors like bilirubin levels, albumin levels, blood clotting time, and the presence of fluid accumulation (ascites). Patients with well-preserved liver function (Child-Pugh A) can tolerate more aggressive treatments, while those with poorer function (Child-Pugh B or C) have more limited options.
- Cancer Stage (BCLC Staging System): The Barcelona Clinic Liver Cancer (BCLC) staging system is widely used to classify the cancer and recommend treatment. It integrates tumor characteristics (size, number), liver function, and the patient’s overall health status to place them into stages from very early (Stage 0) to terminal (Stage D), with specific treatment pathways recommended for each stage.
Treatments for Localized Liver Cancer
For patients whose cancer is confined to the liver, a number of treatments with curative intent are available. The choice depends heavily on whether the patient is a candidate for surgery.
Surgical Resection (Partial Hepatectomy)
Surgical resection involves removing the portion of the liver containing the tumor. This is a potentially curative option for patients with a single tumor and well-preserved liver function. The liver has a unique ability to regenerate, so it can regrow to its normal size after a part of it is removed. However, only a small percentage of patients are candidates for resection, as many have underlying cirrhosis that is too advanced to permit safe removal of liver tissue.
Liver Transplantation
For patients with early-stage cancer but poor liver function due to cirrhosis, a liver transplant offers a dual cure: it removes the cancer while also replacing the diseased liver. Patients must meet strict criteria (known as the Milan criteria or similar guidelines) regarding the size and number of tumors to be eligible for a transplant. These criteria are designed to ensure the best possible outcomes and minimize the chance of the cancer recurring after transplantation.
Local Therapies (Non-Surgical)
For patients with localized cancer who are not candidates for surgery or as a bridge to transplant, several highly effective, minimally invasive local therapies are available. These are typically performed by an interventional radiologist.
Ablation Therapies
Ablation refers to the direct destruction of a tumor using energy. It is a curative option for small tumors (typically less than 3 cm).
- Radiofrequency Ablation (RFA): A needle-like probe is inserted into the tumor under image guidance (CT or ultrasound). The probe emits high-frequency electrical currents, which generate heat and destroy the cancer cells.
- Microwave Ablation (MWA): Similar to RFA, MWA uses a probe to deliver microwave energy to heat and destroy the tumor. It can often create a larger and hotter ablation zone more quickly than RFA.
Embolization Therapies
Embolization involves blocking or reducing the blood supply to the tumor. The liver has a dual blood supply, and tumors derive most of their blood from the hepatic artery. Embolization procedures selectively target the tumor’s blood supply via this artery.
- Transarterial Chemoembolization (TACE): This is the most common treatment for intermediate-stage HCC. A catheter is guided through the femoral artery in the groin up to the hepatic artery branches feeding the tumor. A high concentration of chemotherapy drugs is injected directly into the tumor, followed by embolic agents (tiny particles) that block the artery. This traps the chemotherapy in the tumor and cuts off its blood supply.
- Radioembolization (Y-90): Also known as Selective Internal Radiation Therapy (SIRT), this procedure involves injecting millions of microscopic beads containing a radioactive isotope (Yttrium-90) into the arteries supplying the tumor. The beads become lodged in the small vessels of the tumor and deliver a high dose of radiation directly to the cancer cells while sparing much of the surrounding healthy liver tissue.
Radiation Therapy
The role of radiation therapy in liver cancer has evolved significantly with technological advances. While the liver is sensitive to radiation, modern techniques can deliver treatment very precisely.
- Stereotactic Body Radiation Therapy (SBRT): This technique uses advanced imaging and computer planning to deliver very high doses of radiation to the tumor in just a few treatment sessions. It is a non-invasive option for patients with tumors that cannot be treated with other local therapies.
Systemic Therapies for Advanced Liver Cancer
When liver cancer has spread outside the liver or has advanced to a point where local therapies are no longer effective (BCLC Stage C), systemic therapies are used. These are medications that travel through the bloodstream to treat the cancer throughout the body. Traditional chemotherapy has a very limited role in treating HCC. Instead, modern treatment relies on:
- Targeted Therapy: These drugs work by interfering with specific pathways that cancer cells use to grow and form new blood vessels (a process called angiogenesis). They are typically oral medications taken daily.
- Immunotherapy: These drugs, known as immune checkpoint inhibitors, work by helping the body’s own immune system to recognize and attack cancer cells. Often, immunotherapy is used in combination with a targeted therapy drug, which has become a first-line standard of care for many patients with advanced HCC.
Frequently Asked Questions
1. Why is liver function so important in choosing a liver cancer treatment?
The liver performs many vital functions, and most liver cancers develop in a liver already damaged by a chronic disease like cirrhosis. The patient’s remaining liver function determines which treatments they can safely tolerate. For example, a major surgery like a resection can only be done if the remaining liver is healthy enough to regenerate and support the body. Poor liver function limits treatment options to those that are less stressful on the liver.
2. What is the difference between a liver resection and a liver transplant?
A liver resection (or partial hepatectomy) is a surgery to remove only the part of the liver containing the tumor, leaving the rest of the patient’s own liver in place. It is an option for patients with good underlying liver function. A liver transplant is a more extensive surgery to remove the entire diseased liver and replace it with a healthy donor liver. It is an option for patients with poor liver function but early-stage cancer.
3. What is TACE and how does it work?
TACE, or transarterial chemoembolization, is a minimally invasive procedure for treating liver cancer. It works in two ways: a high dose of chemotherapy is delivered directly to the tumor through a catheter, and then the artery feeding the tumor is blocked with tiny particles. This combined approach kills cancer cells with the chemotherapy while also cutting off the tumor’s blood supply.
4. When is a liver transplant considered for a patient with liver cancer?
A liver transplant is considered for patients who have early-stage hepatocellular carcinoma (tumors within specific size and number limits, known as the Milan criteria) but who also have significant underlying liver disease (cirrhosis) that makes them poor candidates for surgical resection. The transplant treats both the cancer and the failing liver simultaneously.
5. Is traditional chemotherapy used to treat liver cancer?
Systemic, intravenous chemotherapy that is used for many other cancers has been found to be largely ineffective against hepatocellular carcinoma (HCC) and is very rarely used. Instead, chemotherapy is used in a localized way with TACE. For advanced disease that has spread, the primary treatments are newer systemic drugs, specifically targeted therapy and immunotherapy.
6. What is the role of a hepatologist in the cancer care team?
A hepatologist is a liver disease specialist, and their role is critical. They manage the patient’s underlying cirrhosis or other chronic liver disease, monitor their liver function throughout treatment, and manage complications of liver failure. Their expertise is essential in helping the multidisciplinary team decide which cancer treatments are safe and appropriate for the patient.
7. What is the difference between ablation and embolization?
Ablation therapies, like RFA and MWA, are methods of direct tumor destruction. A probe is inserted into the tumor to destroy it with heat. Embolization therapies, like TACE and radioembolization, are treatments delivered through the tumor’s blood supply. They work by blocking the artery that feeds the tumor, either with chemotherapy-delivering particles or with radioactive beads.
